Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Glycemic effect of pancreatic preproglucagon in mouse sleeve gastrectomy
Ki-Suk Kim, Chelsea R. Hutch, Landon Wood, Irwin J. Magrisso, Randy J. Seeley, Darleen A. Sandoval
Ki-Suk Kim, Chelsea R. Hutch, Landon Wood, Irwin J. Magrisso, Randy J. Seeley, Darleen A. Sandoval
View: Text | PDF
Research Article Endocrinology Metabolism

Glycemic effect of pancreatic preproglucagon in mouse sleeve gastrectomy

  • Text
  • PDF
Abstract

Intestinally derived glucagon-like peptide-1 (GLP-1), encoded by the preproglucagon (Gcg) gene, is believed to function as an incretin. However, our previous work questioned this dogma and demonstrated that pancreatic peptides rather than intestinal Gcg peptides, including GLP-1, are a primary regulator of glucose homeostasis in normal mice. The objective of these experiments was to determine whether changes in nutrition or alteration of gut hormone secretion by bariatric surgery would result in a larger role for intestinal GLP-1 in the regulation of insulin secretion and glucose homeostasis. Multiple transgenic models, including mouse models with intestine- or pancreas tissue–specific Gcg expression and a whole-body Gcg-null mouse model, were generated to study the role of organ-specific GLP-1 production on glucose homeostasis under dietary-induced obesity and after weight loss from bariatric surgery (vertical sleeve gastrectomy; VSG). Our findings indicated that the intestine is a major source of circulating GLP-1 after various nutrient and surgical stimuli. However, even with the 4-fold increase in intestinally derived GLP-1 with VSG, it is pancreatic peptides, not intestinal Gcg peptides, that are necessary for surgery-induced improvements in glucose homeostasis.

Authors

Ki-Suk Kim, Chelsea R. Hutch, Landon Wood, Irwin J. Magrisso, Randy J. Seeley, Darleen A. Sandoval

×

Figure 5

Increased intestinal GLP-1 secretion is not necessary in VSG-induced improvements in oral glucose tolerance.

Options: View larger image (or click on image) Download as PowerPoint
Increased intestinal GLP-1 secretion is not necessary in VSG-induced imp...
Plasma total GLP-1 levels 15 minutes after a liquid mixed nutrient gavage in sham versus vertical sleeve gastrectomy (VSG) (A) GcgRAΔPdx1Cre and (B) GcgRAΔVilCre mouse cohorts. **P < 0.01; ***P < 0.001 (2-way ANOVA; genotype × surgery). Total gastric inhibitory polypeptide (GIP) response to the liquid mixed nutrient gavage in sham versus VSG (C) GcgRAΔPdx1Cre and (D) GcgRAΔVilCre mouse cohorts (2-way ANOVA; main effect of surgery). (E) Five-hour fasting blood glucose was significantly lower in VSG versus sham animals (2-way ANOVA; main effect of surgery). Glucose response to an oral glucose load after an i.p. injection of saline (Sal) or exendin 9-39 (Ex9) in sham or VSG (F) control (Ctrl; ***P < 0.001 for sham vs. VSG in each drug-treated group [3-way ANOVA; time × surgery]; ###P < 0.001 for Sal vs. Ex9 in each surgery group [3-way ANOVA; time × drug]). (G) GcgRAΔPdx1Cre, **P < 0.01; for sham versus VSG in each drug-treated group (3-way ANOVA; time × surgery); #P < 0.05; for Sal versus Ex9 in each surgery group (3-way ANOVA; time × drug). (H) GcgRAΔNull (3-way ANOVA; main effect of surgery), and (I) GcgRAΔVilCre mice. **P < 0.01; for sham versus VSG in each drug-treated group (2-way ANOVA; time × surgery). (J) Glucose incremental area under the curve (iAUC) during the oral glucose tolerance test (OGTT) in sham- (J) or VSG-treated (K) GcgRA mouse cohorts. *P < 0.05; ***P < 0.001 (3-way ANOVA; genotype × drug). All data were obtained from cohorts 4 and 5, all animals were tested once per condition, and data are represented as Mean ± SEM. OGTT data from Pdx1Cre and VilCre were combined as control (E, F, J, and K). Control: sham (n = 8 from Pdx1Cre, n = 7 from VilCre), VSG (n = 8 from Pdx1Cre, n = 9 from VilCre); GcgRAΔPdx1Cre: sham (n = 8), VSG (n = 9); GcgRAΔNull: sham (n = 7), VSG (n = 7); GcgRAΔVilCre: sham (n = 6), VSG (n = 6).

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts